- Home
- KITT vs RNAZ Comparison
KITT vs RNAZ Comparison
Compare KITT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KITT
- RNAZ
- Stock Information
- Founded
- KITT 2014
- RNAZ 2016
- Country
- KITT United States
- RNAZ United States
- Employees
- KITT N/A
- RNAZ N/A
- Industry
- KITT Industrial Machinery/Components
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- KITT Industrials
- RNAZ Health Care
- Exchange
- KITT Nasdaq
- RNAZ Nasdaq
- Market Cap
- KITT 5.8M
- RNAZ 4.9M
- IPO Year
- KITT N/A
- RNAZ 2021
- Fundamental
- Price
- KITT $2.26
- RNAZ $3.35
- Analyst Decision
- KITT
- RNAZ Strong Buy
- Analyst Count
- KITT 0
- RNAZ 1
- Target Price
- KITT N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- KITT 17.0M
- RNAZ 143.7K
- Earning Date
- KITT 11-12-2024
- RNAZ 11-14-2024
- Dividend Yield
- KITT N/A
- RNAZ N/A
- EPS Growth
- KITT N/A
- RNAZ N/A
- EPS
- KITT N/A
- RNAZ N/A
- Revenue
- KITT $2,399,852.00
- RNAZ N/A
- Revenue This Year
- KITT $980.78
- RNAZ N/A
- Revenue Next Year
- KITT N/A
- RNAZ N/A
- P/E Ratio
- KITT N/A
- RNAZ N/A
- Revenue Growth
- KITT N/A
- RNAZ N/A
- 52 Week Low
- KITT $0.82
- RNAZ $2.66
- 52 Week High
- KITT $17.14
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- KITT 51.00
- RNAZ 30.32
- Support Level
- KITT $1.91
- RNAZ $2.90
- Resistance Level
- KITT $3.44
- RNAZ $3.50
- Average True Range (ATR)
- KITT 1.02
- RNAZ 0.42
- MACD
- KITT -0.07
- RNAZ 0.31
- Stochastic Oscillator
- KITT 16.74
- RNAZ 50.74
About KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops autonomous robots for the ocean industries. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing of related software to both the commercial and defense business sectors. Nauticus' services provide customers with the necessary data collection, analytics, and subsea manipulation capabilities to support and maintain assets while reducing their operational footprint, operating cost, and greenhouse gas emissions, to improve offshore health, safety, and environmental exposure.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.